BioAge Labs, Inc. BIOA

About BioAge Labs, Inc. (BIOA): stock profile, AI score and financials

BioAge Labs, Inc. (BIOA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BIOA at 27.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,556 of 2,925 stocks — the bottom half of the AI-ranked universe. BIOA scores in the top quartile across revenue growth (98.4), institutional flow (84.8). Areas of concern include free cash flow (2.2) and revenue scale (2.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BioAge Labs, Inc. reports quarterly revenue of $2.5M, net income of $-26.1M, free cash flow of $-19.6M. Top institutional holders of BIOA by reported 13-F value include a16z Capital Management, L.L.C., BlackRock, Cormorant Asset Management, based on the most recent SEC filings. BIOA trades on the Nasdaq exchange and files with the SEC under CIK 1709941. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BIOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioAge Labs, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1709941 →